Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STN1013800 in Acquired Blepharoptosis
NCT06514612Phase 3Recruiting
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial in acquired blepharoptosis comparing STN1013800 BID with Placebo BID (2 arms). Primary endpoint: Marginal Reflex Distance 1 at Day 14. Started Dec 2024; status: recruiting.
02
Drugs
oxymetazoline
03
Conditions
acquired blepharoptosis
Beyond the preview
Go deeper on NCT06514612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514612.